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Using high-throughput chemical and genetic screening, Matheny and colleagues (in this issue ofChemistry &
Biology) identified STF-118804, an inhibitor of nicotinamide phosphoribosyltransferase, as a cell type-
specific inhibitor of mixed-lineage leukemia with MLL chromosomal rearrangements. The approach was
powerful, as is the potential for NAD as a specific cancer target.Philadelphia chromosome-positive chro-
nic myelogenous leukemia remains the
paragon of genotype-targeted cancer
pharmacology. The identification of ABL
kinase activation by BCR-ABL fusion
and the availability of STI-571 as an
ABL-targeted inhibitor have allowed hun-
dreds of thousands of US patients to be
treated with a specific agent (Druker,
2008). Childhood acute lymphoblastic
leukemias (ALL) that are refractory to
treatment frequently contain chromo-
some translocations of the mixed lineage
leukemia (MLL) gene (de Boer et al.,
2013; Muntean and Hess, 2012). The
MLL gene encodes a histone H3 Lys 4
methyltransferase that is essential for
HOX gene expression during develop-
ment. Although mixed lineage leukemia
(MLL) translocations result in loss of the
endogenous methyltransferase domain,
oncogenic MLL fusion proteins are asso-
ciated with a set of transcriptional elon-
gation promoting proteins and the histone
H3 Lys79 methyltransferase DOT1L,
which further enhance target gene
expression (de Boer et al., 2013; Muntean
and Hess, 2012). In addition, the N-termi-
nal menin-binding motif of MLL and
MLL fusions is essential for interactions
with menin, the lens epithelium-derived
growth factor, and chromatin and is
required for leukemogenesis (Muntean
and Hess, 2012). Thus, multiple MLL-
associated factors are potential drug
targets for MLL-rearranged ALL (de Boer
et al., 2013; Muntean and Hess, 2012).
Motivated by the severity of the malig-
nancy and the wealth of potential drug
targets, Matheny et al. (2013; in this issue
of Chemistry & Biology) conducted a
cellular high-throughput screen for lead
compounds that would inhibit prolifera-
tion of MLL-rearranged ALL and possess
little activity against ALL cell lines withoutMLL gene rearrangement. STF-118804
was identified in such screens. To identify
the molecular target of this compound,
they infected an MLL-rearranged cell line
with pools of an 9,300 gene-targeting
shRNA library, which contains 25
knockdown reagents per gene and
identified the shRNAs that were depleted
by selection with STF-118804. The data
indicated that silencing of the nicotin-
amide phosphoribosyltransferase gene
(NAMPT) produced hypersensitivity to
the chemical probe (Matheny et al., 2013).
NAMPT is the enzyme required for
salvage biosynthesis from nicotinamide
to nicotinamide adenine dinucleotide
(NAD). Nicotinamide, like the other NAD
precursor vitamins nicotinate and nicotin-
amide riboside, is a water soluble 3-pyr-
idyl-containing metabolite. STF-11804
bears a strong resemblance to Nampt
inhibitors FK866 and CB30865. All three
are 3-pyridyl compounds with a hydro-
phobic extension (Figure 1). NAD and its
reduced and phosphorylated forms,
NADH, NADP, and NADPH, are essential
for the function of multiple oxidoreduc-
tases in central carbon metabolism. This
is termed the redox function of NAD. In
addition, NAD is a consumed substrate
of Sir2-related protein Lys deacetylases
(sirtuins) and ADPribose-transfer en-
zymes including poly(ADPribose) poly-
merase (PARP). Nonredox functions of
NAD are mediated by enzymes, such as
sirtuins and PARP, that degrade the
NAD dinucleotide to nicotinamide and
ADPribosyl products, necessitating nico-
tinamide salvage in order to maintain
NAD homeostasis (Belenky et al., 2007).
NADH is so central to life that many
common cell viability assays measure it
as a proxy for proliferation. Cellular reduc-
tion of tetrazolium salts such as 3-(4,
5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-Chemistry & Biology 20, November 21, 2013 ªtetrazolium bromide, and phenoxazine
dyes such as resazurin (sold as Cell Titer
Blue) are commonly employed in microti-
ter assays of proliferation and viability.
Because these assays principally report
on NADH-dependent reduction rather
than cell viability, they are ideally suited
to identify NAD-targeting compounds.
Thus, the identification of a Nampt inhibi-
tor as antiproliferative could have been a
trivial result, because inhibition of NAD
salvage necessarily limits the amount of
NADH available to reduce resazurin
independent of whether cells are viable.
However, the investigators clearly
showed that MLL-rearranged cell lines
are hypersensitive to STF-11804-induced
apoptosis (Matheny et al., 2013). Why
then are rearrangedMLL cells so sensitive
to targeting NAD?
Just as NAD is involved in redox biology
and non-redox biology, mechanisms for
genotype-specific cytotoxicity fall into
two classes. MLL fusion complexes play
established roles in epigenetic program-
ming. If MLL-rearranged cells induce the
activity of NAD-consuming enzymes
such as sirtuins and PARP, the resulting
flux from NAD to nicotinamide would
be higher, and such cells might be hyper-
sensitive to inhibition of nicotinamide
salvage. Similarly, if maintenance of the
malignant phenotype depends on activity
of an NAD-consuming enzyme, then NAD
depletion might rob a sirtuin or a PARP of
its limiting substrate.
The redox functions of NAD are also
sources of potential genotype-specific
mechanisms. Cancer cells tend to rely
less on oxidative metabolism than sur-
rounding cells, largely because they are
less driven by ATP production than pro-
duction of nucleotides and lipids (Vander
Heiden et al., 2009). A ramp up of glycol-
ysis, a ramp down of citric acid cycle2013 Elsevier Ltd All rights reserved 1307
Figure 1. Chemical Structures of 3-pyridyl Compounds
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Previewsenzyme gene expression,
and sensitivity to the glyco-
lytic inhibitor 2-deoxy-
glucose have been reported
for ALL cells (Boag et al.,
2006). This would suggest
that the NAD requirements





There is further potential for
genotype-specificity in War-
burgian models, because it
has been shown that p53
mutations in ALL are largely
restricted to cases with MLL




(PPP), which is required for
nucleotide biosynthesis, de-
pends on cytosolic NADP
and produces cytosolic
NADPH for fatty acid syn-




drogenase, such that p53-
normal cells are inhibited
in the use of glucose to
generate NADPH, nucleo-
tides and fatty acids, whilep53 mutant cells are derepressed for the
PPP (Jiang et al., 2011). Consistent with
inhibition of targets in glucose fermenta-
tion and the PPP by targeting NAD,
FK866 is reported to lead to a sharp
decline in nucleocytosolic NAD prior to
affecting mitochondrial NAD pools (Pittelli
et al., 2010). However, someNADmust be
available for redox cycling in mito-
chondria to produce citrate for the sub-
sequent appearance of cytosolic citrate
and conversion to cytosolic acetyl-coA1308 Chemistry & Biology 20, November 21,for fatty acid synthesis (Ghanta et al.,
2013).
Now that Nampt has been identified
as an ALL target, further tumor profiling
is warranted to identify the range of
malignancies that are sensitive. An
exciting possibility is that the therapeutic
window for Nampt inhibitors can be
modulated nutritionally; low NAD pre-
cursor vitamins might be warranted
for the most aggressive chemotherapy,
while provision of nicotinate or nicotin-2013 ª2013 Elsevier Ltd All rights reservedamide riboside might be
warranted either to wash out
from chemotherapy or to pro-
tect nonmalignant tissues
from collateral damage (Bo-
gan and Brenner, 2008).REFERENCES
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